Welcome to our dedicated page for Fosun Internatio news (Ticker: FOSUY), a resource for investors and traders seeking the latest updates and insights on Fosun Internatio stock.
News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
Fosun International (OTC:FOSUF, FOSUY) held its 2026 interim results presentation in Hong Kong on 28 August, reporting first-half Group revenue of RMB86.96 billion and profit attributable to owners of the parent of RMB1.72 billion, a 160.3% year-on-year increase. Overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue.
According to Fosun International, four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — contributed 73.5% of Group revenue. Technology innovation investment in the first half of 2026 was RMB4.2 billion, up 16.7% year-on-year, mainly supporting pharmaceutical and healthcare R&D and a broader global innovation and operating ecosystem.
Fosun International (OTC:FOSUF) announced that its subsidiary ClubMed Lifestyle Group has submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with BNP Paribas, HSBC and J.P. Morgan as joint sponsors. ClubMed Lifestyle Group operates premium all‑inclusive resorts led by the Club Med brand.
According to the listing application materials, ClubMed Lifestyle Group generated EUR 1.95 billion revenue in 2025, up from EUR 1.86 billion in 2023, and achieved adjusted EBITDA of EUR 390 million with a 20.2% margin. The group operates 69 resorts and expects to reach about 85 resorts worldwide by 2030. Upon completion of the proposed listing, proceeds are expected to be used to expand and upgrade its global resort network and to strengthen digital and AI capabilities.
Fosun International (OTC:FOSUF) announced that its subsidiary ClubMed Lifestyle Group has submitted a listing application to the Hong Kong Stock Exchange for a proposed separate listing on the Main Board. ClubMed Lifestyle Group operates premium all-inclusive resorts under the Club Med brand and related vacation concepts using an asset-light model.
Club Med currently runs 69 resorts worldwide and, by business volume in 2025, was the world's largest all-inclusive resort brand. Revenue grew from EUR 1.86 billion in 2023 to EUR 1.95 billion in 2025, while gross profit increased from EUR 540 million to EUR 590 million. Adjusted EBITDA reached EUR 390 million in 2025, with a margin of 20.2%. ClubMed Lifestyle Group expects to operate about 85 resorts by 2030. Proceeds from the proposed listing are planned mainly for global resort expansion, product upgrades, and digital and AI capabilities, with the remainder for capital structure optimisation and daily operations.
Fosun International (OTC:FOSUF, FOSUY) reported 1H2026 total revenue of RMB86.96 billion, broadly stable year-on-year, while profit attributable to owners surged 160.3% to RMB1.72 billion. Industrial operation profit reached RMB3.69 billion, up 17%, reflecting improved operational quality in core sectors including pharmaceuticals, insurance, and cultural tourism.
Overseas revenue rose 5.3% to RMB49.16 billion, accounting for 56.5% of Group revenue, and core subsidiaries generated RMB63.88 billion, or 73.5% of total. According to Fosun International, technology innovation investment grew 16.7% to RMB4.2 billion, while divestments of non-core assets exceeded RMB12.0 billion. As of 30 June 2026, cash, bank balances and term deposits were RMB61.214 billion, and the total debt to total capital ratio improved to 55.7%. The Group’s MSCI ESG rating was upgraded to AAA.
Fosun International (FOSUF, FOSUY) has received three 2026 awards from Global Banking and Finance Review: ESG & Sustainability Awards – Best Sustainable Development Company Asia, CSR Awards – Best CSR Company Asia, and Brand of the Year Awards – Holding Group Brand of the Year Asia.
According to Fosun International, its MSCI ESG rating was raised to AAA in 2026, its FTSE Russell ESG score reached 4.2/5 with continued FTSE4Good inclusion, and it ranked top 1% in S&P Global Sustainability Yearbook (China Edition). Fosun Foundation reports its Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families, while AI Rural Doctor Assistant 2.0 and other AI initiatives and healthcare products from group companies such as Henlius, Fosun Pharma and Fosun Tourism Group are expanding their impact globally.
Fosun International (OTC:FOSUF) received five honors at the 16th Asian Excellence Award 2026. Co-CEOs Chen Qiyu and Xu Xiaoliang were named Asia's Best CEO, while Fosun also earned the Sustainable Asia Award 2026, Best Environmental Responsibility Award and Best Corporate Communications Award.
Fosun highlights upgraded MSCI ESG AAA rating, FTSE Russell ESG score of 4.2/5, inclusion in S&P Global's Sustainability Yearbook 2026, climate targets toward 2050 carbon neutrality, innovative cancer and malaria treatments, and large-scale social programs through Fosun Foundation.
Fosun International (OTC:FOSUF) was included in the S&P Global Sustainability Yearbook (China Edition) 2026, ranking among China’s Top 1% for the third straight year. Fosun scored 73 in the 2025 Corporate Sustainability Assessment and ranks in the top 7% of global industry peers. The group also holds an MSCI ESG AAA rating, has been in the FTSE4Good Index for five years, and targets carbon peak by 2028 and carbon neutrality by 2050, alongside a 20% reduction in Scope 1 and 2 emissions intensity by 2034 versus 2024.
Fosun International (OTC:FOSUF) released its 2025 ESG Report and fourth Climate Information Disclosures Report on April 28, 2026. Key disclosures include a mid-term target to reduce Scope 1 and 2 GHG intensity by 20% by 2034 (2024 base), a commitment to peak emissions by 2028 and achieve carbon neutrality by 2050, and completion of a USD910 million three-year sustainability-linked syndicated loan. The Group reports upgraded ESG scores (MSCI AAA) and highlights green certifications, sustainable tourism progress, health‑care pipeline milestones, and total assets of RMB716.2 billion as of December 31, 2025.
Fosun International (OTC:FOSUF) reported 2025 revenue of RMB173.43 billion and adjusted industrial operation profit of RMB4 billion. Adjusted NAV was RMB133.5 billion (NAV per share HKD18.1). The Group booked a RMB23.4 billion non-cash impairment, largely real estate-related.
Core units generated RMB128.2 billion (74% of revenue); Fosun Pharma net profit rose 21.69% to RMB3.371 billion. Management announced a share buyback, asset disposals, a USD205 million bond tender, and targets to exceed RMB10 billion net profit and cut interest-bearing debt below RMB60 billion.
Fosun International (OTC:FOSUF) reported 2025 results and management commentary on March 31, 2026. Adjusted NAV totaled RMB133.5 billion, with a NAV per share of HKD18.1. Group revenue was RMB173.43 billion and adjusted industrial operation profit was RMB4.0 billion.
The company booked a non-cash book loss of RMB23.4 billion from impairments (≈55% real estate, ≈45% non-core goodwill/intangibles). Management announced a share buyback program, insiders and the major shareholder will increase holdings, and said it will focus resources on core, high-growth businesses.